$CARM
Carisma Therapeutics Inc

2014 Q4 Form 10-Q Financial Statement

#000119312514411366 Filed on November 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $375.0K $539.0K $622.0K
YoY Change -26.47% -13.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.210M $2.270M $790.0K
YoY Change 55.63% 187.34% -15.05%
% of Gross Profit
Research & Development $5.260M $8.872M $3.376M
YoY Change 63.86% 162.8% -11.85%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K $110.0K
YoY Change 0.0% -9.09% 0.0%
% of Gross Profit
Operating Expenses $7.470M $11.14M $4.162M
YoY Change 61.34% 167.68% -12.56%
Operating Profit -$7.095M -$10.60M -$3.540M
YoY Change 72.21% 199.49%
Interest Expense -$140.0K -$74.00K -$289.0K
YoY Change -84.44% -74.39% 312.86%
% of Operating Profit
Other Income/Expense, Net -$910.0K -$72.00K -$273.0K
YoY Change 1720.0% -73.63%
Pretax Income -$8.140M -$10.67M -$3.810M
YoY Change 60.55% 180.05% -20.95%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.139M -$10.67M -$3.813M
YoY Change 60.66% 179.94% -20.89%
Net Earnings / Revenue -2170.4% -1980.33% -613.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$487.1K -$662.7K -$2.323M
COMMON SHARES
Basic Shares Outstanding 16.29M shares 16.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.10M $35.90M $3.900M
YoY Change 584.81% 820.51%
Cash & Equivalents $54.06M $35.94M $3.881M
Short-Term Investments
Other Short-Term Assets $300.0K $300.0K $200.0K
YoY Change 200.0% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $54.40M $36.29M $4.200M
YoY Change 577.47% 764.07%
LONG-TERM ASSETS
Property, Plant & Equipment $486.0K $585.0K $900.0K
YoY Change -35.97% -35.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $19.00K $11.00K $0.00
YoY Change -99.19%
Total Long-Term Assets $599.0K $690.0K $900.0K
YoY Change -81.32% -23.33%
TOTAL ASSETS
Total Short-Term Assets $54.40M $36.29M $4.200M
Total Long-Term Assets $599.0K $690.0K $900.0K
Total Assets $55.00M $36.98M $5.100M
YoY Change 389.45% 625.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.458M $2.588M $700.0K
YoY Change 40.78% 269.71%
Accrued Expenses $1.987M $1.656M $300.0K
YoY Change 133.76% 452.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $3.400M
YoY Change -100.0%
Long-Term Debt Due $300.0K $1.600M $1.700M
YoY Change -81.25% -5.88%
Total Short-Term Liabilities $5.202M $6.507M $7.100M
YoY Change -2.82% -8.35%
LONG-TERM LIABILITIES
Long-Term Debt $9.700M $1.600M $3.300M
YoY Change 234.48% -51.52%
Other Long-Term Liabilities $4.000K $100.0K $800.0K
YoY Change -99.43% -87.5%
Total Long-Term Liabilities $4.000K $1.700M $4.100M
YoY Change -99.89% -58.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.202M $6.507M $7.100M
Total Long-Term Liabilities $4.000K $1.700M $4.100M
Total Liabilities $5.206M $8.200M $11.20M
YoY Change -41.51% -26.79%
SHAREHOLDERS EQUITY
Retained Earnings -$91.75M -$83.61M
YoY Change 59.3%
Common Stock $18.00K $16.00K
YoY Change 800.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.83M $28.78M -$6.100M
YoY Change
Total Liabilities & Shareholders Equity $55.00M $36.98M $5.100M
YoY Change 389.45% 625.12%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$8.139M -$10.67M -$3.813M
YoY Change 60.66% 179.94% -20.89%
Depreciation, Depletion And Amortization $100.0K $100.0K $110.0K
YoY Change 0.0% -9.09% 0.0%
Cash From Operating Activities -$7.140M -$8.690M -$3.180M
YoY Change 134.1% 173.27% -26.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.25M -390.0K -10.00K
YoY Change 255.13% 3800.0% -100.75%
NET CHANGE
Cash From Operating Activities -7.140M -8.690M -3.180M
Cash From Investing Activities 0.000 -10.00K 0.000
Cash From Financing Activities 25.25M -390.0K -10.00K
Net Change In Cash 18.11M -9.090M -3.190M
YoY Change 346.06% 184.95% 2.9%
FREE CASH FLOW
Cash From Operating Activities -$7.140M -$8.690M -$3.180M
Capital Expenditures $0.00 -$10.00K $0.00
Free Cash Flow -$7.140M -$8.680M -$3.180M
YoY Change 134.1% 172.96% -25.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16289359 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3881000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16134515 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16134515 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1159965 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.99
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
541315 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.81
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.39
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1492606 shares
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
45000
CY2014Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
6000
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6507000
CY2014Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
1645000
CY2014Q3 us-gaap Interest Payable Current
InterestPayableCurrent
111000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
16000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2588000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83611000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1656000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
28778000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36981000
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
112373000
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
165000
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
621000
CY2014Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1642000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
690000
CY2014Q3 us-gaap Construction Payable Current
ConstructionPayableCurrent
690000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35943000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
585000
CY2014Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
35943000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
348000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000
CY2014Q3 us-gaap Assets
Assets
36981000
CY2014Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
35943000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5353000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
355000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3200000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
36291000
CY2014Q3 ebio Estimated Milestone Payment To Be Received
EstimatedMilestonePaymentToBeReceived
25000000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7882000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1636137 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1636137 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
77688009 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.39
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1346238 shares
CY2013Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
10000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
297000
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2876000
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
79000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1746000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57594000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
850000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-54332000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11237000
CY2013Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
297000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3260000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
182000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
297000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1115000
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1642000
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
297000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
346000
CY2013Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
62000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7942000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
759000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
7942000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
88000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10437000
CY2013Q4 us-gaap Assets
Assets
11237000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7942000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2354000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
8030000
CY2013Q4 ebio Deferred Offering Cost
DeferredOfferingCost
180000
CY2013Q2 us-gaap Collaborative Arrangement Rights And Obligations
CollaborativeArrangementRightsAndObligations
The Company has granted ThromboGenics an exclusive, sublicensable, royalty-bearing license under the Company's rights in these patent rights and know-how, as well as under any other patent rights and know-how that the Company controls during the research term that are necessary for ThromboGenics to perform its obligations to research, develop, manufacture and commercialize collaboration products.
CY2013Q2 us-gaap Collaborative Arrangement Nature And Purpose
CollaborativeArrangementNatureAndPurpose
Under this agreement, the Company and ThromboGenics are collaborating to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease.
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1320000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.87
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8652057 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-106000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12358000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-505000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-601000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-96000
us-gaap Revenues
Revenues
824000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
83000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15674000
us-gaap Net Income Loss
NetIncomeLoss
-12959000
us-gaap Interest Paid
InterestPaid
197000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1658000
us-gaap Operating Expenses
OperatingExpenses
13182000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10576000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4001000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
99000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3000000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
335000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6436000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-210000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
us-gaap Paid In Kind Interest
PaidInKindInterest
28000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3500000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2606000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-437000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2715000
us-gaap Share Based Compensation
ShareBasedCompensation
755000
ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
287000
ebio Fair Value Adjustment Of Convertible Notes Payable
FairValueAdjustmentOfConvertibleNotesPayable
188000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M15D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.72
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
dei Trading Symbol
TradingSymbol
EBIO
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M9D
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22169000
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7390 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
205265 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13954000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.74
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M2D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.42
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.90
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1645709 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
51507 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
258000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25836000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-237000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-181000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56000
us-gaap Revenues
Revenues
1868000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1249000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
137000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26536000
us-gaap Net Income Loss
NetIncomeLoss
-26017000
us-gaap Interest Paid
InterestPaid
177000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-804000
us-gaap Operating Expenses
OperatingExpenses
27704000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21445000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28001000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
311000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
50307000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
984000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-137000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000
us-gaap Paid In Kind Interest
PaidInKindInterest
28000
us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6259000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1692000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
519000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
51505000
us-gaap Share Based Compensation
ShareBasedCompensation
1945000
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000
ebio Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
-50000
ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
56678000
ebio Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Reclassification To Equity
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityReclassificationToEquity
247000
ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
247000
ebio Collaborative Arrangement Date Of Agreement
CollaborativeArrangementDateOfAgreement
2013-05-28
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1390000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.39
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3540000
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-289000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-273000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000
CY2013Q3 us-gaap Revenues
Revenues
622000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4718000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3813000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
4162000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3376000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
786000
CY2013Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
905000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
326000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16098000 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10602000
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-74000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-72000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8872000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2014Q3 us-gaap Revenues
Revenues
539000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10674000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-10674000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
11141000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2269000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
808000
CY2014Q3 ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0

Files In Submission

Name View Source Status
0001193125-14-411366-index-headers.html Edgar Link pending
0001193125-14-411366-index.html Edgar Link pending
0001193125-14-411366.txt Edgar Link pending
0001193125-14-411366-xbrl.zip Edgar Link pending
d806302d10q.htm Edgar Link pending
d806302dex311.htm Edgar Link pending
d806302dex312.htm Edgar Link pending
d806302dex321.htm Edgar Link pending
ebio-20140930.xml Edgar Link completed
ebio-20140930.xsd Edgar Link pending
ebio-20140930_cal.xml Edgar Link unprocessable
ebio-20140930_def.xml Edgar Link unprocessable
ebio-20140930_lab.xml Edgar Link unprocessable
ebio-20140930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g806302dsp_017.jpg Edgar Link pending
g806302dsp_019.jpg Edgar Link pending
g806302dsp_021a.jpg Edgar Link pending
g806302dsp_021b.jpg Edgar Link pending
g806302dsp_022.jpg Edgar Link pending
g806302dsp_024.jpg Edgar Link pending
g806302dsp_025a.jpg Edgar Link pending
g806302dsp_025b.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending